Analysis of cardiovascular diseases after the upload phase with intravitreal ranibizumab and bevacizumab in patients with exudative age-related macular degeneration

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
C FischerH Hoerauf

Abstract

The intravitreal administration of vascular endothelial growth factor (VEGF) inhibitors is the gold standard in the treatment of exudative age-related macular degeneration (AMD) but the possible risks of systemic, particularly cardiovascular side effects are still discussed. We prospectively followed 111 patients at the University Hospital in Göttingen with exudative AMD and intravitreal ocular treatment with bevacizumab and ranibizumab during the upload phase of 3 months using a questionnaire for documentation of possible cardiovascular events. In 5 out of 111 patients angina pectoris was observed and in 6 patients the antihypertensive medication had to be increased. No differences were found between bevacizumab and ranibizumab. A patient with pre-existing cardiovascular diseases suffered a stroke in the upload phase but no thromboembolic events were observed in the other patients. In this small but prospective clinical study no increased risk for cardiovascular events during the upload phase of the VEGF inhibitors ranibizumab and bevacizumab could be detected when taking the age and pre-existing cardiovascular diseases into consideration.

References

Jun 1, 1992·Ophthalmology·R KleinK L Linton
Jun 1, 1989·Archives of Ophthalmology·N M BresslerH R Taylor
Feb 1, 1995·Ophthalmology·J R VingerlingP T de Jong
Feb 1, 1993·Journal of Epidemiology and Community Health·R A Mitchell
Jan 1, 1995·Epidemiologic Reviews·J R VingerlingP T de Jong
Jun 10, 2000·Arteriosclerosis, Thrombosis, and Vascular Biology·I ZacharyJ Martin
Feb 15, 2001·Progress in Retinal and Eye Research·J R Evans
May 15, 2001·American Journal of Physiology. Cell Physiology·N Ferrara
May 14, 2003·Archives of Ophthalmology·Ronald KleinKaren J Cruickshanks
Aug 2, 2003·The New England Journal of Medicine·James C YangSteven A Rosenberg
Mar 12, 2004·American Journal of Ophthalmology·Ronald KleinTien Y Wong
May 12, 2004·Archives of Ophthalmology·Sandra C TomanyMichael D Knudtson
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Oct 8, 2004·Nature Biotechnology·Mark Ratner
Jun 24, 2005·Klinische Monatsblätter für Augenheilkunde·S Michels, P J Rosenfeld
Sep 29, 2005·Expert Opinion on Biological Therapy·David Ternant, Gilles Paintaud
Jan 25, 2007·Acta Ophthalmologica Scandinavica·Marcus KerntAnselm Kampik
Jul 27, 2007·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·M KerntA Kampik
Sep 1, 2007·Seminars in Ophthalmology·Rima M DaferWalter M Jay
Feb 13, 2010·Stroke; a Journal of Cerebral Circulation·Chao-Chien HuHerng-Ching Lin
Dec 1, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F A B SchutzT K Choueiri
Dec 9, 2010·The Journal of Biological Chemistry·Jan Terje AndersenCaroline Ekblad
Jan 6, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Toni K ChoueiriFabio A B Schutz
Apr 30, 2011·The New England Journal of Medicine·UNKNOWN CATT Research GroupGlenn J Jaffe
Feb 27, 2015·Demography·Aïda Solé-AuróEileen Crimmins
May 30, 2015·Investigative Ophthalmology & Visual Science·Claus ZehetnerGerhard F Kieselbach

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.